Thyroid Eye Disease Market Top Companies Study - Horizon Therapeutics, Viridian Therapeutics, Pierre Fabre/ACELYRIN, HanAll Biopharma/Harbour BioMed/Immunovant, and Sling Therapeutics.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Thyroid Eye Disease Market - (By Marketed Treatment (TEPEZZA (Teprotumumab), By Pipeline Treatment (VRDN 001, VB 421, Batoclimab, Linsitnib)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."

According to the latest research by InsightAce Analytic, the Thyroid Eye Disease Market is valued at USD 2.26 billion in 2024 , and it is expected to reach USD 4.02 billion by the year 2034 , with a CAGR of 6.0% during the forecast period of 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2893

Thyroid eye disease (TED), also referred to as Graves' orbitopathy or Graves' ophthalmopathy, is an autoimmune disorder characterized by inflammation and swelling around the eyes. The global market for TED therapeutics is projected to grow steadily in the coming years, driven primarily by the rising prevalence of the condition. Additional factors contributing to market expansion include advancements in autoimmune disease treatment, improved healthcare infrastructure, and high levels of patient adherence to prescribed therapies.

Moreover, increasing disposable incomes and the expansion of research and development initiatives are expected to create significant revenue opportunities for industry stakeholders. Substantial investments by key market players, coupled with ongoing innovations in end-use product development, are further enhancing market prospects. Government support in promoting the use of artificial tears and lubricating eye drops to manage symptoms such as ocular dryness is also expected to support the market's growth trajectory.

List of Prominent Players in the Thyroid Eye Disease Market:
• Horizon Therapeutics
• Viridian Therapeutics
• Pierre Fabre/ACELYRIN
• HanAll Biopharma/Harbour BioMed/Immunovant
• Sling Therapeutics
• Other Market Players

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics
Drivers:
The increasing prevalence of thyroid eye disease (TED) is a major factor anticipated to drive market growth. Enhanced patient adherence to treatment protocols and continuous advancements in autoimmune disease therapies are also expected to significantly contribute to the global TED market's revenue expansion. Furthermore, rising investments in research and development activities by pharmaceutical and biotechnology companies are projected to further support the market's growth trajectory.

Challenges:
Despite positive developments, several challenges may hinder market expansion. Notably, the lack of a definitive cure for TED and limited awareness, particularly in emerging markets, are likely to restrain growth. Additionally, the high cost of treatment may limit accessibility, further impeding overall market development. The COVID-19 pandemic exacerbated these challenges by disrupting global supply chains, halting production activities, and limiting product distribution. These disruptions have led to substantial financial losses for stakeholders across the TED industry, including manufacturers, suppliers, and retailers.

Regional Trends:
North America is anticipated to dominate the thyroid eye disease market, securing a significant revenue share and projected to grow at a robust compound annual growth rate (CAGR) in the forecast period. This growth is driven by the high incidence of thyroid disorders, ongoing therapeutic advancements, and intensive R&D efforts by leading market players. Europe also holds a notable market position due to its mature healthcare infrastructure and increased adoption of novel treatment strategies. Moreover, the presence of key industry participants and rising collaborative efforts aimed at expanding geographic reach are expected to bolster market growth across both regions.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2893

Recent Developments:
• In March 2024, ACELYRIN, INC. announced positive proof-of-concept results from a Phase 1⁄2 trial of lonigutamab in thyroid eye condition that is now underway. Lonigutamab is a subcutaneous (SC) humanized IgG1 monoclonal antibody that aims the insulin-like growth factor-1 receptor (IGF-1R), a known mechanism of action for thyroid eye disease treatment.

Segmentation of Thyroid Eye Disease Market-
By Marketed Treatment-
• TEPEZZA (Teprotumumab)
By Pipeline Treatment-
• VRDN 001
• VB 421
• Batoclimab
• Linsitnib
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/thyroid-eye-disease-market/2893

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.